The Dreem site uses necessary Cookies to allow you to access the site and the Services in an optimal way. According to your consent, the Dreem website also uses Cookies for audience measurement. You are free to accept or decline all cookies or to customize your choice by clicking on the corresponding buttons.
You can change this choice at any time and modify your consent by going to "manage my cookies" available on every page of the site.
We will retain your choices regarding your consent for a period of 6 months.
For more information, you can consult our Cookie Policy available on each page of our site.

When you visit Dreem's website, two types of cookies may be placed on your device, the necessary cookies and the audience measurement cookies.
A cookie is a piece of information, identified by a name, that can be sent to your browser by a website you are visiting. Your web browser will store it for a period of time, and send it back to the web server each time you log in.
To benefit from all the features offered by Dreem's website, the necessary cookies are mandatory.
You are free to refuse the activation of the audience measurement cookies. If you refuse the activation of cookies, your information will not be tracked during your visit on this site. Only one cookie will be used in your browser so that this choice can be respected in the future.We will retain your consent choices for a period of 6 months.
You can change this choice at any time and modify your consent by going to "manage my cookies" available on every page of the site.
For more information, you can consult our Cookie Policy available on each page of our site.

  • For individuals
  • For research
  • Company
  • Careers
  • Contact us

    • We are Dreem

    Here is the story of how we got here,
    and where we're going.

    Scroll
    OUR MISSION

    Redefining sleep care,
    to improve health at scale

    With hundreds of millions of people negatively impacted, sleep disorders have become a growing public health epidemic. But despite their high prevalence, sleep disorders remain largely unidentified and untreated, with serious obstacles in terms of diagnosis, treatment and engagement.

    At Dreem, we’re on a mission to redefine how sleep is managed, to improve health at scale.

    OUR VISION

    A future where everyone gets the sleep they need, to live the life they want

    Dreem was founded on a simple idea: that everyone should have access to the best sleep care, anywhere in the world. Today we’re delivering on that promise, by building the healthcare of tommorow, one night at a time.

    OUR APPROACH

    Our unique alliance of sleep medicine and technology

    By combining the best sleep experts, with cutting edge technology, we are creating new ways of delivering sleep care.

    A truly integrated and personalized approach, with technologies that connect patients to experts and extend the reach of care. With the highest standard of care at every touchpoint, Dreem improves health outcomes and decisions in the long-run.

    A team of 50 experts,
    on a mission to solve
    sleep disorders

    Our open positions

    From sleep research, neuroscience, behavioral therapies, mechanical engineering, machine learning, electronic design, embedded systems, testing, ergonomics, development of property applications and software, product design, and much more...

    We are united by one common goal: pushing the boundaries of sleep science, to bring real positive change to sleepers around the world.

    Our open positions

    Our Advisory Boards

     
     
     

    Raphaël Heinzer

    Associate professor and director of the Sleep Center (CIRS) at Lausanne University Hospital (CHUV). His expertise covers the physiology and epidemiology of various sleep disorders - from sleep apnea, insomnia, hypersomnia, to parasomnia.

    Director of the Sleep Center (CIRS) at Lausanne University Hospital

    Emmanuel Mignot

    Dr. Mignot is the Craig Reynolds Professor of Sleep Medicine in the Department of Psychiatry and Behavioral Sciences at Stanford University and the Director of the Stanford Center for Narcolepsy. Accepted as an authority on sleep research and medicine, he is even recognized as having discovered the cause of narcolepsy.

    Director, Center for Sleep Sciences and Medicine at Stanford

    Jean-Louis Pépin

    Both his expertise as a sleep physician, and his decades of experience in the field of research, has made him one of the most prominent figures of sleep research. As the head of the Physiology Department at the CHU Grenoble, and Director of the HP2 Laboratory, he specializes in the management of all sleep and respiratory pathologies.

    Medical Director of the Sleep Center at CHU Grenoble

    avatar
    avatar
    avatar
    Medical
    Advisory Board
     
     
     
     
    Business
    Advisory Board

    Anne Reiser

    Anne Reiser has run her entire career in the medical device scene. Working with companies including Medtronic, Zimmer, American Home Product, and Mölnlycke in key leadership positions across France, Europe and Asia, she has become a recognized expert in the field of respiratory care.

    Former President of EMEA-APAC Japan and
    President of Europe at ResMed Inc

    Donald Jones

    A globally recognized leader in digital medicine, digital therapies, technology enabled health services and virtual-first healthcare delivery. With over two decades of experience as a founder, independent Board Member or Advisory Board member of numerous companies - his expertise covers applied technology enabling mobility, connectivity and network effect in healthcare, and value based pricing solutions.

    Derek Hill

    With more than 25 years of experience in digital health and medical imaging, Derek Hill is President of Panoramic Digital Halth and part time Professor of Medical Imaging Sciences at UCL. His experience in leadership positions and entrepreneurial ventures make him an expert on the evolving regulatory environment for digital health technologies to support drug development and as medical devices.

    Steve Atkinson

    His career in medical devices spans over 30 years, including various CEO and senior leadership positions at Johnson & Johnson, GE Healthcare, Zeltique Aesthetics, or Altlantic Therapeutics. Not to forget his experience as an entrepreneur, with multiple startups, turnarounds and succesful exits over the years.

    avatar
    avatar
    avatar
    avatar

    Our journey

    2021 2021

    Dreem builds a digital sleep to provide better sleep solutions for all. With the launch of Dreem 3, the firm creates a one of a kind and clinically validated solution to assess sleep in both inbound and outbound settings. Dreem also reaches space, with the headband being tested by Thomas Pesquet in the ISS as part of the ALPHA mission.

    2020 2020

    A new validation paper published in the prestigious SLEEP journal, proves that the accuracy of Dreem’s hardware and algorithms are equivalent to that of a PSG and a sleep expert analysis. This new validation, coupled with the explosion of digital health support the firm’s B2B shift.

    2019 2019

    Dreem 2 - FDA registered as a Class 2 medical device - is launched, and Dreem crosses the Atlantic by opening a New York office. The firm pushes the boundaries of research by opening its first call for proposals for innovative research projects, and receives a growing amount of attention from health providers looking for ways to study sleep.

    2018 2018

    A stepping stone in Dreem’s history, with €60 million raised from leading investors, enabling the startup to rapidly accelerate product development, invest in research and development, and advance the future of sleep tech. With the launch of a CBT-i app and the publication of 3 papers, Dreem steps up as a sleep pionneer.

    2017 2017

    Dreem grows in scientific credibility and legitimacy, by putting together a world-class scientific advisory board with some of the world’s leading sleep experts - from Raphael Heinzer, Emmanuel Mignot, to Russel Foster. June 2017 also sees the launch to the general public of the Dreem Headband in Europe and the US.

    2016 2016

    With over 7,000 applicants, the Dreem First beta testing program is launched and tested on 500 early adopters. A golden opportunity to gather feedback, iterate, and utimately refine the product to better suit the needs of patients. In parallel, Dreem’s first clinical trial is conducted.

    2015 2015

    Starting as a duo, the team quickly grows to 12 experts. Engineers, as well as PhD students are recruited to build and test a new technology to monitor and improve sleep. By the end of 2015, the company files 10 patents and has its first functional prototype: the Dreem headband is born.

    2014 2014

    A public academic research finding becomes the keystone of a private company. Two engineering students - Quentin Soulet de Brugière and Hugo Mercier - hear about a discovery involving audio stimulation and deep sleep. After delving into the field of sleep research, they quickly realize how much of a real sleep solution is needed.